High C-Reactive Protein/Low Serum Albumin: A Hidden Villain in Cardiovascular Disease

Manolis, Antonis S.; Manolis, Antonis A.

doi:10.1177/00033197221120135

Cited by 3 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mental stress analyzer uses the principle of heart rate variability to analyze the patient's mental and physical stress quantitatively. Heart rate variability refers to the small differences in the intervals between heartbeats, which results from the adjustment of the sinoatrial node of the heart by the autonomic nervous system [22]. This subtle distinction can mirror the functioning of the autonomic nervous system, indicating its level of activity, balance, and coordination, thereby objectively reflecting the stress on the brain.…”

Section: Discussionmentioning

confidence: 99%

Psychological Stress Analysis to Evaluate the Effects of Transcranial Magnetic Stimulation on Mood Regulation and Quality of Life in Patients with Bipolar Disorder

Qiang,

Yang,

Yang

2024

Actas Esp Psiquiatr

View full text Add to dashboard Cite

Objective: To explore the impact of transcranial magnetic stimulation on emotion regulation and quality of life in patients with bipolar disorder (BD) and to evaluate the effectiveness of the mental stress analyzer. Methods: Patients with BD admitted to our hospital from August 2022 to August 2023 were retrospectively selected. For the present study, 60 patients who received drug therapy served as the control group, and the other 60 patients who received repeated transcranial stimulation on this basis served as the observation group. The heart rate variability (HRV) of the two groups of patients was detected by a mental stress analyzer/HRV analysis system. Hamilton Depression Rating Scale (HAMD), Self-Rating Anxiety Scale (SAS), and Self-Rating Depression Scale (SDS) were used to evaluate the mental state of the two groups of patients. The quality of life of the two groups was assessed using the Comprehensive Quality of Life Questionnaire 74 (GQOLI-74). Clinical effectiveness global rating scale-illness severity (CGI-SI) was used to evaluate the clinical symptoms of the two groups of patients, and the incidence of adverse reactions was calculated. Results: In comparison to the control group, the high-frequency power (HF) of the patients demonstrated an elevation in the observation group, and the low-frequency power (LF) and LF/HF were significantly reduced (p < 0.05). The standard deviation of NN intervals (SDNN), standard deviation of all five-minute NN intervals (SDANN), root mean square of successive differences (rMSSD), and percent RR intervals with a difference in duration higher than 50 ms (PNN50) of patients in the observation group showed a notable increase compared to the control group (p < 0.05). Compared with the control group, the HAMD, SAS, and SDS scores of the patients in the observation group demonstrated a substantial decline relative to the control group (p < 0.05). In contrast to the control group, there was a significant increase in the overall clinical effectiveness rate among patients in the observation group, and the incidence of adverse reactions was significantly reduced (p < 0.05). Conclusions: Repetitive transcranial magnetic stimulation (rTMS) has significant clinical effects in treating BD and can effectively improve patients' anxiety, suppress emotions, and regulate patients' emotions. At the same time, rTMS has high safety and little impact on the balance of patients' autonomic nervous function, reduces the incidence of adverse reactions, accelerates the patient's recovery process, and is suitable for clinical promotion.

show abstract

Section: Discussionmentioning

confidence: 99%

Psychological Stress Analysis to Evaluate the Effects of Transcranial Magnetic Stimulation on Mood Regulation and Quality of Life in Patients with Bipolar Disorder

Qiang,

Yang,

Yang

2024

Actas Esp Psiquiatr

View full text Add to dashboard Cite

show abstract

“…This study highlights the significance of inflammation and dialysis adequacy indicators in predicting the occurrence of CVC in HD patients. CRP, which is commonly used as a marker of inflammation, serves as a traditional cardiovascular risk factor in non-HD patients and is highly effective in HD patients [ 12 , 13 ]. This underscores the need for clinicians to pay close attention to CRP levels when assessing the CVC risk in this patient population.…”

Section: Discussionmentioning

confidence: 99%

Time-Dependent Factors Influencing Cardiocerebral Vascular Events in Chronic Hemodialysis Patients: Insights from a Longitudinal Study

Zhong,

Zhang,

et al. 2023

Med Sci Monit

View full text Add to dashboard Cite

Background Cardiocerebral vascular events (CVCs) are significant complications in patients undergoing hemodialysis (HD). Given the increased morbidity and mortality associated with CVCs in this population, understanding the factors influencing CVC occurrence over time is crucial. This study aimed to investigate these time-dependent factors in HD patients. Material/Methods A total of 228 HD patients from 2 dialysis centers, with at least 3 months of treatment between 2017 and 2021, were included. Annual clinical data were collected, and patients were monitored until CVC development. Kaplan-Meier analysis and a time-dependent Cox regression model were used for data analysis. Results The mean age of 228 patients was 55.0±15.0 years, and 64.76% were male. For 5 years of monitoring, the mean follow-up interval was 3.1±1.0 years for patients to develop CVCs. The 1-year, 3-year, and 5-year CVC-free rates were 97.47%, 81.31%, and 70.71%, respectively. Time-dependent Cox regression revealed that C-reactive protein was an independent time-dependent risk factor in HD patients and blood flow rate was an independent time-dependent protective factor. The male subgroup and non-diabetic subgroup had these same results. The following were was the independent time-dependent risk factors: white blood cell count for the female subgroup; blood flow rate for the non-elderly subgroup; and C-reactive protein for the diabetic subgroup. None were risk factors for the elderly subgroup. Conclusions It took an average of 3.1±1.0 years for patients with HD to develop CVCs. C-reactive protein and blood flow rate emerged as key time-dependent influencing factors for CVCs in this population.

show abstract

“…Перитонеальні макрофаги щурів збирали за допомогою перитонеального лаважу й інкубували з СРБ чи без нього. При 5 мкг/мл СРБ збільшив експресію гена EMMPRIN щодо GAPDH, виміряну за допомогою RT-PCR, у 1,67 ± 0,07 раза через 24 години, 1,85 ± 0,49 раза через 48 годин (р < 0,05) [24]. Експресія гена MMP-9 за наявності СРБ при 5 мкг/мл супроводжувалася збільшенням у 1,36 ± 0,11 раза через 24 години, в 3,95 ± 0,81 раза через 48 годин (р < 0,05).…”

Section: обговоренняunclassified

Clinical and prognostic significance of C-reactive protein in the conditions of stable angina pectoris in combination with chronic obstructive pulmonary disease stage II–III

Dotsenko,

Kraidashenko

2023

ZMJ

View full text Add to dashboard Cite

The aim of the study: to evaluate the clinical and prognostic value of the altered C-reactive protein expression level in functional class II–III stable angina pectoris combined with chronic obstructive pulmonary disease (COPD) stage II–III. Materials and methods. In accordance with the goal of the study, 122 individuals were examined being assigned to 4 clinical groups: Group 1 – 30 patients with ischemic heart disease (IHD, functional class II–III stable angina pectoris, mean age 56.93 ± 1.25 years; male / female ratio 86.67 % / 13.33 %); Group 2 – 30 patients with COPD stage II–III (mean age 57.99 ± 1.12 years; male / female ratio 80.0 % / 20.0%); Group 3 – 40 patients with IHD + COPD (mean age 56.48 ± 1.16 years; male / female ratio 76.92 / 23.08 %) and Group 4 – 22 apparently healthy individuals (mean age 54.37 ± 1.84 years old, male / female ratio 77.50 % / 22.50 %). Results. Significant correlations have been found between the level of C-reactive protein (CRP) and troponin I (r = +0.71 and r = +0.82, p < 0.01 for both pairs) in IHD and IHD + COPD groups. When the level of CRP expression was elevated, a clear increase in the level of cardiospecific proteins (troponin I) was seen, which could indicate a damage to the myocardium. A positive association was found between the CRP level and the CAT scale score in COPD and IHD+COPD groups (r = +0.65 and r = +0.73, respectively, p < 0.05) indicating a significant association between the processes of systemic inflammation and the dynamics of a patient’s subjective condition, caused mainly by the severity of ventilatory and respiratory disorders and pulmonary obstruction. The relative risk for cardiorespiratory fitness impairment (according to 6MWD) in patients with a high level of CRP (>6 mg/L) was almost 13 times higher (EER 80.0 % CER 6.25 %, RR = 12.8 at 95 % CI, which was 1.87–87.56, р < 0.001), while the odds ratio was 60 (OR = 60.0 with CI 4.69–767.85, р < 0.001), compared to patients with a CRP level <6 mg/L, indicating systemic inflammatory process progression in the development of a negative prognosis of IHD combined with COPD. Conclusions. The study and examination of the CRP level is necessary as a prognostic predictor for assessing the risk for developing cardiovascular complications in ІHD combined with COPD.

show abstract

High C-Reactive Protein/Low Serum Albumin: A Hidden Villain in Cardiovascular Disease

Cited by 3 publications

References 16 publications

Psychological Stress Analysis to Evaluate the Effects of Transcranial Magnetic Stimulation on Mood Regulation and Quality of Life in Patients with Bipolar Disorder

Psychological Stress Analysis to Evaluate the Effects of Transcranial Magnetic Stimulation on Mood Regulation and Quality of Life in Patients with Bipolar Disorder

Time-Dependent Factors Influencing Cardiocerebral Vascular Events in Chronic Hemodialysis Patients: Insights from a Longitudinal Study

Clinical and prognostic significance of C-reactive protein in the conditions of stable angina pectoris in combination with chronic obstructive pulmonary disease stage II–III

Contact Info

Product

Resources

About